New immune cell attack tested for Tough-to-Treat lung cancer
NCT ID NCT07498595
Summary
This early-phase study is testing the safety of a two-part treatment for advanced lung cancer that has become resistant to standard targeted drugs. It combines a patient's own tumor-fighting immune cells (called TILs) with a newer generation of the targeted drug they were already taking. The goal is to see if this combination can control the cancer's growth and is safe for up to 50 patients who have run out of other options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR-TKI-RESISTANT NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.